2 results
Approved WMOCompleted
Phase 1b:Primary:- To evaluate the safety and tolerability and determine the recommended Phase 2 dose (RP2D) and schedule of ALRN-6924 when administered to patients with TP53-mutated extensive disease (ED) small cell lung cancer (SCLC) receiving…
Approved WMOCompleted
The primary objective is to determine the limited-efficacy of both the experimental systems in comparison to our previous cohort that was treated with the more traditional MCGR. Limited-efficacy will be determined in terms of maintenance of the…